Oruka Therapeutics, Inc. (ORKA)
- Previous Close
9.62 - Open
9.60 - Bid 6.86 x 200
- Ask 11.94 x 200
- Day's Range
9.15 - 9.77 - 52 Week Range
5.49 - 53.88 - Volume
115,883 - Avg. Volume
261,705 - Market Cap (intraday)
363.547M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-- - Earnings Date May 14, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
39.14
Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 1 trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.
orukatx.comRecent News: ORKA
View More
Performance Overview: ORKA
Trailing total returns as of 5/14/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ORKA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ORKA
View MoreValuation Measures
Market Cap
360.18M
Enterprise Value
-11.57M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-70.95M
Diluted EPS (ttm)
--
Balance Sheet and Cash Flow
Total Cash (mrq)
375.65M
Total Debt/Equity (mrq)
0.25%
Levered Free Cash Flow (ttm)
--